Clinical information of 5 AHI patients
| Subjectsa | Age (gender) | Days since infectionb | Viral load copies/ml | CD4 count cells /µl | Plasma anti–HIV-1 gp41 | Fiebig stagec | ||||
| EIA | Western blot | IgM | IgG | IgA | ||||||
| 065-0 | 35 (M) | 17 | 391 | 269 | Neg. | Neg. | Neg. | Neg. | Neg. | 2/1 |
| 068-9d | 37 (M) | 30 | 258 | 611 | Pos. | Neg. | Pos. | Neg. | Neg. | 3 |
| 681-7 | 42 (M) | 20 | 5,900,000 | 230 | Neg. | Neg. | Neg. | Neg. | Neg. | 2/1 |
| 684-6 | 32 (M) | 20 | 10,925,000 | 225 | Pos. | Neg. | Pos. | Pos. | Pos. | 3 |
| 001-4 | 26 (M) | 20 | 4,700,000 | 165 | Pos. | Ind. | Pos. | Pos. | Pos. | 4 |
| Subjectsa | Age (gender) | Days since infectionb | Viral load copies/ml | CD4 count cells /µl | Plasma anti–HIV-1 gp41 | Fiebig stagec | ||||
| EIA | Western blot | IgM | IgG | IgA | ||||||
| 065-0 | 35 (M) | 17 | 391 | 269 | Neg. | Neg. | Neg. | Neg. | Neg. | 2/1 |
| 068-9d | 37 (M) | 30 | 258 | 611 | Pos. | Neg. | Pos. | Neg. | Neg. | 3 |
| 681-7 | 42 (M) | 20 | 5,900,000 | 230 | Neg. | Neg. | Neg. | Neg. | Neg. | 2/1 |
| 684-6 | 32 (M) | 20 | 10,925,000 | 225 | Pos. | Neg. | Pos. | Pos. | Pos. | 3 |
| 001-4 | 26 (M) | 20 | 4,700,000 | 165 | Pos. | Ind. | Pos. | Pos. | Pos. | 4 |
EIA, enzyme immunoassay; Neg., negative; Pos., positive; Ind., indeterminate, as one or more bands are present but the blot did not meet the criteria for positive in that at least one of gp160 and/or gp120, gp41, or gp24 must be present.
Patient no. 068-9 received ART for 7 d after exposure, 21 d before blood and bone marrow samples were obtained from.
Days since infection were determined by clinical information of last contact or by days from onset of AHI symptoms. All patients had admitted to hospitals of recent contact except 684-6, who had AHI symptoms and had negative Western blot analysis with high plasma viral load.
Based on description reported by Fiebig et al (2003).
All five subjects were quickly placed on antiretroviral therapy soon after diagnosis and consequently none developed detectable autologous or heterologous neutralizing antibodies during up to 2 yr of follow up (unpublished data).